NovaScan
Chicago
About NovaScan
NovaScan provides diagnostic products that apply bioelectrical impedance to assess tissue characteristics relevant to cancer detection. Its MarginScan device performs ex vivo and in vivo margin evaluation by generating immediate electrical measurements during clinical procedures. The nsCanary tool examines biopsy cores directly after sampling to indicate whether malignant tissue is present. NovaScan also uses machine-learning models to interpret impedance signatures and distinguish cancerous from non-cancerous tissue. These products are designed to support clinical decision-making through rapid, instrument-based analysis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $11.2M
- Funding stage: Early Stage Venture
- Last round: Grant (Nov 2025)
- Website: novascaninc.com
- Phone: 312-952-7701
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/novascan-55537 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.